Chemical Compound Review:
Vatalanib butanedioic acid; N-(4-chlorophenyl)-4...
Synonyms:
PTK-787, CHEMBL75232, PTK787, SureCN675786, PTK/ZK, ...
This record was replaced with 151194.
- Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. Morgan, B., Thomas, A.L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M.A., Mross, K., Ball, H.A., Lee, L., Mietlowski, W., Fuxuis, S., Unger, C., O'Byrne, K., Henry, A., Cherryman, G.R., Laurent, D., Dugan, M., Marmé, D., Steward, W.P. J. Clin. Oncol. (2003)
- Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Müller, M., Wood, J., Martiny-Baron, G., Unger, C., Marmé, D. Cancer Res. (2000)
- Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Zips, D., Eicheler, W., Geyer, P., Hessel, F., Dörfler, A., Thames, H.D., Haberey, M., Baumann, M. Cancer Res. (2005)
- PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Drevs, J., Müller-Driver, R., Wittig, C., Fuxius, S., Esser, N., Hugenschmidt, H., Konerding, M.A., Allegrini, P.R., Wood, J., Hennig, J., Unger, C., Marmé, D. Cancer Res. (2002)
- Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Kitagawa, Y., Dai, J., Zhang, J., Keller, J.M., Nor, J., Yao, Z., Keller, E.T. Cancer Res. (2005)
- Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Liu, Y., Poon, R.T., Li, Q., Kok, T.W., Lau, C., Fan, S.T. Cancer Res. (2005)
- The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Lin, B., Podar, K., Gupta, D., Tai, Y.T., Li, S., Weller, E., Hideshima, T., Lentzsch, S., Davies, F., Li, C., Weisberg, E., Schlossman, R.L., Richardson, P.G., Griffin, J.D., Wood, J., Munshi, N.C., Anderson, K.C. Cancer Res. (2002)
- Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Riesterer, O., Honer, M., Jochum, W., Oehler, C., Ametamey, S., Pruschy, M. Clin. Cancer Res. (2006)
- Targeting vascular endothelial growth factor pathway offers new possibilities to counteract microvascular disturbances during ischemia/reperfusion of the pancreas. von Dobschuetz, E., Meyer, S., Thorn, D., Marme, D., Hopt, U.T., Thomusch, O. Transplantation (2006)
- A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Thomas, A., Trarbach, T., Bartel, C., Laurent, D., Henry, A., Poethig, M., Wang, J., Masson, E., Steward, W., Vanhoefer, U., Wiedenmann, B. Ann. Oncol. (2007)
- Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Solorzano, C.C., Baker, C.H., Bruns, C.J., Killion, J.J., Ellis, L.M., Wood, J., Fidler, I.J. Cancer Biother. Radiopharm. (2001)
- PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Wood, J.M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., Persohn, E., Rösel, J., Schnell, C., Stover, D., Theuer, A., Towbin, H., Wenger, F., Woods-Cook, K., Menrad, A., Siemeister, G., Schirner, M., Thierauch, K.H., Schneider, M.R., Drevs, J., Martiny-Baron, G., Totzke, F. Cancer Res. (2000)
- Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. Thomas, A.L., Morgan, B., Horsfield, M.A., Higginson, A., Kay, A., Lee, L., Masson, E., Puccio-Pick, M., Laurent, D., Steward, W.P. J. Clin. Oncol. (2005)
- The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Sini, P., Wyder, L., Schnell, C., O'Reilly, T., Littlewood, A., Brandt, R., Hynes, N.E., Wood, J. Clin. Cancer Res. (2005)
- Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. Nykänen, A.I., Krebs, R., Tikkanen, J.M., Raisky, O., Sihvola, R., Wood, J., Koskinen, P.K., Lemström, K.B. Transplantation (2005)
- The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. Saishin, Y., Saishin, Y., Takahashi, K., Seo, M.S., Melia, M., Campochiaro, P.A. Invest. Ophthalmol. Vis. Sci. (2003)
- Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Drevs, J., Zirrgiebel, U., Schmidt-Gersbach, C.I., Mross, K., Medinger, M., Lee, L., Pinheiro, J., Wood, J., Thomas, A.L., Unger, C., Henry, A., Steward, W.P., Laurent, D., Lebwohl, D., Dugan, M., Marmé, D. Ann. Oncol. (2005)
- Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Wood, J.M. Medicina (B Aires) (2000)